MBA Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: MBA Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $49.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

MBA Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $49.6K Trade | TransData Nexus

MBA Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $49.6K Total Trade · DGFT Verified

MBA Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $49.6K across 3 products in 1 therapeutic categories. Based on 25 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Lapatinib ($25.7K), Carfilzomib ($17.8K), Procarbazine ($6.1K).

MBA Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

MBA Pharmaceuticals Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is MBA Pharmaceuticals Private Limited? — Company Overview & Market Position

MBA Pharmaceuticals Private Limited is a privately held pharmaceutical company established on February 26, 2014, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U51397DL2014PTC265441. Its authorized and paid-up capital stands at ₹2 million each. The registered office is located at 4931, Plot No. 68, Second Floor, South Ansari Road, Daryaganj, New Delhi, Delhi, 110002.

MBA Pharmaceuticals specializes in the wholesale and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company exports to over 40 countries, primarily in the European Union, Middle East and North Africa (MENA), South Asian Association for Regional Cooperation (SAARC), Southeast Asia, African Gulf Cooperation Council (GCC), and Commonwealth of Independent States (CIS) regions.

As of the latest available data, the company has a modest annual turnover, with an employee count ranging from 11 to 50. The directors of MBA Pharmaceuticals are Jitender Kumar and Girish Kalra, both appointed on February 26, 2014.

What Does MBA Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Lapatinib$25.7K

Product Portfolio — Top 3 by Export Value

MBA Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lapatinib	Advanced Oncology	$25.7K	6	0.5%	4
2	Carfilzomib	Advanced Oncology	$17.8K	13	1.5%	6
3	Procarbazine	Advanced Oncology	$6.1K	6	2.3%	6

MBA Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $49.6K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

MBA Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

MBA Pharmaceuticals operates manufacturing facilities compliant with international standards, including Good Manufacturing Practice (GMP) and ISO 9001:2015 certifications. These facilities are equipped to produce a range of pharmaceutical products, ensuring quality and safety in line with global requirements.

3Key Leadership

The leadership team of MBA Pharmaceuticals comprises:

Jitender Kumar: Director since February 26, 2014.

Girish Kalra: Director since February 26, 2014.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does MBA Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

MBA Pharmaceuticals has established a presence in several regulated markets, including the European Union (EU), Middle East and North Africa (MENA) region, and South Asian Association for Regional Cooperation (SAARC) countries. The company exports a diverse portfolio of products, including oncology, hepatitis-C, nephrology, HIV, vaccines, rheumatic, branded and generic medicines, and COVID-19 products.

2Emerging Markets

MBA Pharmaceuticals has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international standards, such as Good Distribution Practice (GDP) and ISO 9001:2015 certifications, facilitates its entry into these markets.

3Geographic Strategy

MBA Pharmaceuticals demonstrates a diversified geographic strategy by exporting to over 40 countries across various regions, including the EU, MENA, SAARC, Southeast Asia, African GCC, and CIS countries. This broad market presence mitigates concentration risk and positions the company as a competitive player in the global pharmaceutical export sector.

MBA Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding MBA Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company holds ISO 9001:2015 certification, indicating a commitment to quality management systems.

2WHO & EU GMP

MBA Pharmaceuticals' manufacturing facilities are certified with Good Manufacturing Practice (GMP) and ISO 9001:2015, ensuring compliance with international quality standards. However, specific certifications such as WHO prequalification and EU GMP certificates are not publicly disclosed.

3CDSCO & Indian Regulatory

MBA Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory standards. The company also possesses the necessary export No Objection Certificates (NOCs) for international trade.

MBA Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

MBA Pharmaceuticals operates in a competitive landscape with numerous pharmaceutical exporters from India. While specific market share data is not publicly available, the company's diverse product portfolio and international certifications position it as a competitive entity in the global pharmaceutical export market.

2Key Differentiators

MBA Pharmaceuticals' key differentiators include its compliance with international standards such as GDP and ISO 9001:2015, a diverse product portfolio encompassing oncology, hepatitis-C, nephrology, HIV, vaccines, rheumatic, branded and generic medicines, and COVID-19 products, and its export to over 40 countries across various regions.

3Strategic Position

MBA Pharmaceuticals focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's adherence to international standards and diverse product portfolio indicate a strategic direction aimed at expanding its global presence and competitiveness in the pharmaceutical export sector.

Buyer Due Diligence Brief — Evaluating MBA Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

MBA Pharmaceuticals demonstrates a commitment to quality and regulatory compliance through its ISO 9001:2015 and GMP certifications. The company's export volume and consistency are evidenced by its presence in over 40 countries, including the EU, MENA, SAARC, Southeast Asia, African GCC, and CIS regions.

2Certifications to Verify

Importers should verify the following certifications when considering MBA Pharmaceuticals as a supplier:

ISO 9001:2015: Confirms the company's adherence to quality management systems.

Good Manufacturing Practice (GMP): Ensures compliance with international manufacturing standards.

Good Distribution Practice (GDP): Verifies the company's compliance with distribution standards.

These certifications can typically be verified through the company's official website or by contacting the company directly.

Frequently Asked Questions — MBA Pharmaceuticals Private Limited

How many pharmaceutical products does MBA Pharmaceuticals Private Limited export from India?

MBA Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Lapatinib ($25.7K), Carfilzomib ($17.8K), Procarbazine ($6.1K). Total export value is $49.6K.

What is MBA Pharmaceuticals Private Limited's total pharmaceutical export value?

MBA Pharmaceuticals Private Limited's total pharmaceutical export value is $49.6K, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does MBA Pharmaceuticals Private Limited cover?

MBA Pharmaceuticals Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 3 products).

Get Full MBA Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.